Atara Biotherapeutics (ATRA) EBT Margin (2021 - 2026)
Atara Biotherapeutics' (ATRA) quarterly EBT Margin came in at 767.14% in Q2 2026, down 78074.0% on a YoY basis from N/an in Q2 2025, and up 4.5% quarter-over-quarter from 803.29% in Q1 2026.
Powered by 
Analysis
Atara Biotherapeutics (ATRA) EBT Margin (2021 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has reported EBT Margin for 6 consecutive years, with 767.14% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBT Margin fell 78074.0% year-over-year to 767.14%; the trailing twelve-month figure through Jun 2026 stood at 268.66% (down 27172.0% YoY), and the FY2025 full-year result was 27.11%, up 9335.0% from the prior year.
- EBT Margin improved to 767.14% in Q2 2026 per ATRA's latest filing, from 803.29% in the prior quarter.
- Across five years, EBT Margin topped out at 38.73% in Q1 2025 and bottomed at 30110.89% in Q4 2022.
- Historically, EBT Margin has averaged 2973.08% across 5 years, with a median of 489.78% in 2025.
- The sharpest annual moves came in 2022 and 2023: EBT Margin plunged 2887182 bps in 2022, then soared 2868361 bps in 2023.
- Over 5 years, EBT Margin stood at 30110.89% in 2022, then surged by 95 bps to 1427.28% in 2023, then jumped by 97 bps to 38.81% in 2024, then sank by 447 bps to 212.41% in 2025, then sank by 261 bps to 767.14% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 767.14%, 803.29%, and 212.41% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | 55.43% |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | -885.91% |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | -49.02% |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | 14.32% |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | -1,356.24% |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | -24,299.18% |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 36.51% |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | -0.44% |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 2.88% |
| 10 | Atara Biotherapeutics | 148.00 Mn | 131.45 Mn | 439,000.00 | -767.14% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -767.14% |
| Mar 31, 2026 | -803.29% |
| Dec 31, 2025 | -212.41% |
| Sep 30, 2025 | -123.81% |
| Jun 30, 2025 | 13.60% |
| Mar 31, 2025 | 38.73% |
| Dec 31, 2024 | -38.81% |
| Sep 30, 2024 | -54.56% |
| Jun 30, 2024 | -66.51% |
| Mar 31, 2024 | -115.98% |
| Dec 31, 2023 | -1,427.28% |
| Sep 30, 2023 | -3,265.48% |
| Jun 30, 2023 | -7,430.20% |
| Mar 31, 2023 | -6,096.98% |
| Dec 31, 2022 | -30,110.89% |
| Sep 30, 2022 | -1,885.65% |
| Jun 30, 2022 | 35.80% |
| Mar 31, 2022 | -1,204.61% |
| Dec 31, 2021 | -1,239.07% |
| Sep 30, 2021 | -1,576.61% |